Deals, pipeline readouts and company news from across biotech and pharma.
Phathom kept its full-year VOQUEZNA guidance at $310–325 million while a US court allowed it to intervene in BDR Pharmaceuticals' suit over the drug's NCE exclusivity.
Eli Lilly reported third-quarter revenue of $24.4bn, driven mainly by Mounjaro and Zepbound, and cited several recent US FDA approvals alongside higher full-year guidance.
The medtech group reported growth both as reported and organically, a lower adjusted profit on a higher tax rate, and the retirement of $864m of debt through a tender offer.
Insmed lifted the low end of 2026 sales guidance for Brinsupri and Arikayce, while the FDA set a January 2027 PDUFA date for an Arikayce label expansion.
Keytruda, Winrevair and Animal Health drove Merck's third-quarter growth, while the FDA accepted a priority-review filing for sacituzumab tirumotecan in advanced or recurrent endometrial cancer.
The US biopharma company reported strong third-quarter growth led by Opzelura and its haematology/oncology portfolio, and lifted full-year net sales guidance for several categories.
The royalty-focused biopharma company reported a GAAP net loss of $28.5m for the quarter and raised adjusted diluted earnings guidance, while reaffirming its revenue outlook.
The company reported third-quarter revenue of $2.94 billion, lifted its full-year outlook excluding Bausch + Lomb and announced a $50 million share repurchase programme.
The Invisalign and iTero maker reported higher aligner sales but weaker scanner revenue, and said discretionary dental spending remains soft.
Glaukos reported record Q3 net sales driven by iDose TR and the newly approved Epioxa, lifted its 2026 outlook and set a preliminary $1bn target for 2027.
The brain and spine delivery device maker reported higher neurosurgery sales, a thinner gross margin and a first formal BLA submission by a partner in Huntington's disease.
MiMedx's October 2026 investor presentation says its proposed Sanara MedTech acquisition faces an FTC Second Request and HSR waiting period, with Hayfin debt financing committed.
MIMEDX reported $62M in Q3 net sales, down from $114M, while citing a court ruling on AXIOFILL and a $25M patent licence deal.
The presbyopia eye-drop maker reported a 50% quarter-on-quarter sales rise, announced a Q4 reorganisation and filed VIZZ in three more markets, while its CEO steps down on 1 December.
The Nasdaq-listed company will trade as AZR from 29 October, with a new executive team and an oral AhR agonist expected to enter Phase 1 in the first half of 2027.
Vanda Pharmaceuticals reports higher third-quarter product sales and lower spending, while flagging planned sNDA filings, a BYSANTI launch and two FDA milestones in December.
Biogen reported a 49% jump in Growth Portfolio revenue, helped by SYFOVRE and EMPAVELI, and raised the low end of its 2026 non-GAAP EPS guidance.
The US hospital operator says people losing exchange coverage cut pre-tax income by about $400m, yet it expects 2026 results in the upper half of guidance.
The contract research and analytics group reported $3.2bn in R&D Solutions net new bookings, while a review of inactive trials trimmed its contracted backlog by about $2.1bn.
The bioprocessing supplier reported third-quarter sales of $209.3 million, up 11%, and said the BioLife deal extends its reach into cell therapy consumables.
Aclaris says its anti-TSLP/anti-IL-4Rα bispecific cut EASI scores by 58% versus 13% on placebo at day 57 in atopic dermatitis, from small cohorts.
The company reported $286.0m in third-quarter ARCALYST net revenue and lifted its full-year outlook, while confirming timelines for its KPL-387 and KPL-1161 pipeline programmes.
The Nasdaq-listed company says third parties have approached it about its biologics contract manufacturer and that it has hired an investment bank, with no sale yet agreed.
Corxel US and Amanat Acquisition Corp. have signed a business combination agreement, with a roughly $300 million PIPE and about $75 million in trust earmarked for oral obesity candidate CX11.
The bleached paperboard maker refinanced all its debt and booked $17.5M in insurance proceeds, but an Augusta mill disruption extended into October.
Initial PrisMN data presented at ASN Kidney Week show PLA2R antibody reductions and early remissions with the anti-CD19 antibody, with no treatment-related serious adverse events reported.
Nasdaq-listed DataMEDS AI has signed a revised letter of intent with five counterparties, targeting a Q4 2026 close, though the deal remains subject to definitive agreements and several approvals.
Pro forma financials for a merger agreed on 14 July 2026 show Senti Biosciences Holdings with about $3.1 million in cash after handing its operating units to ST NewCo Limited.
The Belgian biopharma now expects low-twenties revenue growth and low- to mid-forties adjusted EBITDA growth at constant exchange rates, citing US performance of its two key products.
Roche reports Group sales of CHF 46.5 billion for the first nine months, led by Pharmaceuticals, alongside a run of US FDA approvals, Priority Reviews and a diagnostics clearance.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.